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Immunologic function and survival in hemodialysis patients.
Background. Although the medical determinants of mortality in patients
with end-stage renal disease (ESRD) treated with hemodialysis (HD) are
well appreciated, the contribution of immunologic parameters to survival
in such patients is unclear, especially when variations in age, medical
comorbidity and nutrition are controlled. In addition, although dysregu-
lation of cytokine metabolisn has been appreciated in patients with ESRD,
the association of these parameters with outcomes has not been estab-
lished. Recently, the type of dialyzer used in patients’ treatment has been
associated with survival, but the mechanisms underlying these findings,
including their immune effects, have not been established. We conducted
a prospective, cross-sectional, observational multicenter study of urban
HD patients to determine the contribution of immunological factors to
patient survival. We hypothesized increased proinflammatory cytokines
would be associated with increased mortality, and that improved immune
function would be associated with survival.
Methods. Patients were assessed using demographic and anthropometric
indices, Kt/V, protein catabolic rate (PCR) and immunologic variables
including circulating cytokine [interleukin (IL)-1, IL-2, IL-4, IL-5, IL-6,
IL-12, IL-13 and tumor necrosis factor (TNF)-a] levels, total hemolytic
complement activity (CH50), and T cell number and function. A severity
index, previously demonstrated to be a mortality marker, was used to
grade medical comorbidity. A Cox proportional hazards model, control-
ling for patients’ age, severity index, level of serum albumin concentration,
dialyzer type and dialysis site was used to assess relative survival risk.
Results. Two hundred and thirty patients entered the study. The mean
(6 SD) age of the population was 54.4 6 14.2 years, mean serum albumin
concentration was 3.86 6 0.47 g/dl, mean PCR was 1.1 6 0.28 g/kg/day,
and mean Kt/V 1.2 6 0.3. Patients’ serum albumin concentration was
correlated with levels of Kt/V and PCR, and their circulating IL-13 and
TNF-a levels, but negatively with their circulating IL-2 levels, T-cell
number and T-cell antigen recall function. T-cell antigen recall function
correlated negatively with PCR, but not Kt/V. There was no correlation of
any other immune parameter and medical or demographic factor. Im-
mune parameters, however, were all highly intercorrelated. Mean level of
circulating cytokines in HD patients were in all cases greater than those of
a normal control group. There were few differences in medical risk factors
or immune parameters between patients treated with different types of
dialyzers. After an almost three-year mean follow-up period, increased
IL-1, TNF-a, IL-6, and IL-13 levels were significantly associated with
increased relative mortality risk, while higher levels of IL-2, IL-4, IL-5,
IL-12, T-cell number and function, and CH50 were associated with
improved survival. The difference in survival between patients treated with
unmodified cellulose dialyzers and modified or synthetic dialyzers ap-
proached the level of statistical significance, but there were no differences
in levels of circulating cytokines between these two groups.
Conclusions. Higher levels of circulating proinflammatory cytokines are
associated with mortality, while immune parameters reflecting improved
T-cell function are associated with survival in ESRD patients treated with
HD, independent of other medical risk factors. These factors may serve as
markers for outcome. The mechanism underlying the relationship of
immune function and survival, and the effect of interventions to normalize
immune function in HD patients should be studied.
The medical determinants of mortality in patients with
end-stage renal disease (ESRD) treated with hemodialysis
(HD) consist of older age, presence of diabetes mellitus,
and to a lesser extent, of comorbid conditions such as
cardiovascular and cerebrovascular disease, cancer, colla-
gen vascular disease and chronic obstructive pulmonary
disease [1]. For the United States’ ESRD population,
African-American and women patients tend to have better
survival [1]. The role of nutrition [2, 3] and dose of dialysis
administered (Kt/V) [2–6] in improving survival in HD
patients has been increasingly appreciated. Recently, a
study has suggested the type of dialyzer used for chronic
patient treatment may have an impact on patients’ survival
[7]. The mechanism underlying this effect has been poorly
understood.
Several studies have suggested various aspects of im-
mune dysregulation in HD patients [8–11], but few studies
have linked these factors to medical parameters, or with
outcome. We hypothesized higher levels of circulating
proinflammatory cytokines would be associated with mor-
tality, while immune parameters associated with improved
T-cell function would be associated with survival in ESRD
patients treated with HD, independent of other medical
risk factors. In order to test these hypotheses, we prospec-
tively studied the interrelationship between medical and
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nutritional factors, dose of dialysis, and immunologic func-
tion in patients with ESRD treated with HD.
METHODS
Patient population and demographics of the study
hemodialysis units
Patient recruitment began September 1, 1992 and con-
cluded March 31, 1996. The observation period ended
August 31, 1996. George Washington University Medical
Center’s Ambulatory Dialysis Unit (GWUMC), Howard
University Medical Center’s Dialysis Unit (HUMC), and
the Washington Veterans Affairs Medical Center Dialysis
Unit (VAMC), all in Washington D.C., were the study sites.
The population of the three units was primarily composed
of African-American patients. All patients enrolled in
chronic ESRD HD programs at the GWUMC, HUMC and
VAMC dialysis units, with the exception of HIV infected
patients, hospitalized patients, patients who had a psychi-
atric diagnosis of psychosis and patients who scored less
than 23 on a mini-mental status exam [12] were eligible.
Patients were assigned to treatment with diffferent types of
dialyzers at the different centers by ten different nephrolo-
gists, according to unit policy, personal preference and
clinical considerations. Written informed consent was ob-
tained at GWUMC and HUMC, while verbal consent was
obtained prior to each patient’s enrollment at the VAMC.
The study was approved by the institutional review boards
of the three medical centers. Twenty-eight healthy subjects,
not taking medications, were recruited as controls for the
evaluations of circulating cytokine levels, after being as-
sessed with normal physical and screening laboratory ex-
aminations. All subjects had normal blood pressure, normal
levels of blood urea nitrogen and serum creatinine concen-
tration, and normal urinalyses.
Medical risk factors
Disease severity (the product of age and the relative
mortality risk of comorbid conditions such as diabetes
mellitus, cardiovascular and cerebrovascular disease, colla-
gen vascular disease, malignancy and the type of renal
disease) was quantified by the ESRD severity coefficient
[13], previously validated by a survival analysis in a large
sample of ESRD patients.
Nutritional and dialytic parameters
Protein catabolic rate (PCR) and Kt/V were calculated
monthly at GWUMC and HUMC, and quarterly at VAMC
using the percent urea reduction method as outlined by
Jindal, Manuel and Goldstein [14] and used previously in
other studies [2]. The mean of the patients’ three sequential
monthly serum albumin concentrations after enrollment
was determined. Mid-arm circumference and arm muscle
area were obtained by trained personnel at study entry, as
previously described [15–17]. Dialyzer type was not deter-
mined by the study protocol, but was noted for each patient
at the time of assesssment of immune variables and cate-
gorized as (1) unmodified cellulose, (2) modified cellulose
or (3) synthetic [7].
Immunologic variables
Immunologic variables were assessed in patients in the
three dialysis units at the time of their regular monthly
laboratory evaluations. Blood samples obtained before
initiating HD were immediately processed for recovery of
plasma and lymphocytes. Briefly, plasma was removed,
aliquoted, and stored at 270°C. The buffy coat was care-
fully removed, layered on a Ficol-Hypaque (Sigma Chem-
ical Co., St. Louis, MO, USA) gradient and spun at 800 g
for 12 minutes.
Evaluation of cell mediated immunity was performed by
subtyping lymphocytes using fluorescein-labeled antibodies
(Anti-CD3, -CD4, -CD8, or -CD19; PharmMinGen, San
Diego, CA, USA). Additionally, T-cell functional studies
[18, 19] were performed by coincubating the isolated
lymphocytes with a panel of common antigens (purified
protein derivative, streptolysin, candida extract, and teta-
nus toxoid; Allergenic, Mountain View, CA, USA). The
cells were washed prior to the addition of 0.2 mCi of
tritiated thymidine to each tube, then pulsed for 18 hours at
37°C, washed in medium and harvested. The incorporated
radioactivity present in each cell pellet was measured in a
Beckman LS3801 scintillation counter (Beckman Instru-
ments, Fullerton, CA, USA) and the mean counts of
triplicate samples expressed as an antigen recall stimulation
index, using the following formula:
Stimulation index 5
Average cpm of each triplicate sample
Average cpm of the media controls
Total complement activity (CH50) was measured using a
hemolytic assay (Kallestad, Austin, TX, USA) [20]. Circu-
lating cytokine [interleukin (IL)-1, IL-2, IL-4, IL-5, IL-6,
IL-12, IL-13, and tumor necrosis factor (TNF)-a] concen-
trations were detected and measured by a chemilumines-
cence-enhanced capture ELISA modification [20, 21] of the
technique described by Thorpe et al [22] using specific
antibodies directed against each cytokine (R & D Systems,
Minneapolis, MN and Bachem Biosciences, Inc., King of
Prussia, PA, USA) of interest.
Statistical methods
Stability of immunological variables was assessed by
correlating individuals’ T-cell numerical and functional,
cytokine levels at study entry, and at a second assessment
90 to 270 days thereafter in 163 of the 230 subjects, as
previously described [17]. All of the circulating cytokines
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displayed positively skewed distributions. Log transforma-
tions produced relatively symmetric distributions in all
cases. Correlations between demographic data, medical
risk factors, and immunologic factors were assessed by
Spearman Rank Order correlation coefficients, because of
the skewed distributions of the immunologic data, as
previously described [17]. Because of the number of com-
parisons assessed, P 5 0.01 was taken as the level of
statistical significance for correlations. Differences between
groups were assessed by unpaired t-tests, the Wilcoxon test
for comparison of data not distributed normally, chi-square
analysis and analysis of variance (ANOVA) as appropriate.
Survival time for each individual patient was determined
by the number of days between the initial study evaluation
and the end of the study observation period or date of
death. Survival status was confirmed using the Health Care
Finance Administration data base, obtained through
ESRD Network 5 (Richmond, VA, USA) for all patients
enrolled in the study. Cox proportional hazards regression
was used to predict mortality hazard [23]. A separate
equation was calculated for each medical and demographic
predictor (age at time of entry into the study, gender,
severity coefficient, serum albumin concentration, dialyzer
type, and Kt/V determined at study entry).
Following the results of these initial bivariate Cox regres-
sions, regression analyses were performed in which the
relationship between immunologic variables and survival
were examined while simultaneously controlling for predic-
tor medical risk factors, specifically patients’ age, severity
coefficient, level of serum albumin concentration, dialyzer
type and dialysis site. Relative risks or hazards represent
the expected change in mortality risk associated with a 1 SD
increase in the predictor variable, except for dialysis site,
dialyzer type and gender, or as otherwise noted. This allows
for comparison of the effects of changes in levels of several
risk factors across different parameters in a population
[24]. For log transformed variables, the standardized rela-
tive risk represents the increased risk associated with a
100% increase (or doubling) of the untransformed predic-
tor variable. Analyses were performed using PROC
PHREG in SAS 6.12 (SAS Institue Inc., Cary, NC, USA)
using the exact method for ties. The alpha level of tests of
survival and group differences was 0.05. Data are presented
as mean 6 SD.
RESULTS
Demographics
The total enrolled sample comprised 230 subjects (Table
1), representing an enrollment rate of 56.8% of eligible
subjects in the three units. Ninety-three percent of our
patient population was comprised of African-Americans;
30.9% were female, and 57.8% had diabetes mellitus. The
mean age of our patient population was 54.4 6 14.2 years.
The patients had received renal replacement therapy for a
mean and median of 33.7 6 47.3 months and 15.7 months,
respectively, at the time of enrollment. The patients’ mean
PCR was 1.1 6 0.28 g/kg/day, mean Kt/V was 1.2 6 0.3, and
mean serum albumin concentration was 3.86 6 0.47 g/dl.
The mean arm muscle area and upper arm circumference
in our study population was 545.6 6 190 cm2, and 30.3 6
6.2 cm, respectively. Mean and median follow-up times
were 35.4 6 8.3 and 38.4 months, respectively. All the
healthy controls were African-Americans. The mean age of
the 11 male and 17 female healthy controls was 52.1 6 5.5
years. There was no difference in mean age between the
men and the women in the control group.
Characteristics of patients treated with different dialyzer
types
Regarding dialyzer types, 41.3% of patients were treated
with unmodified cellulose, 14.3% with modified cellulose
and 44.3% with synthetic dialyzers. 92.1% of patients at the
VAMC, 55.1% of patients at GWUMC, and 1.1% of
patients at HUMC were treated with synthetic dialyzers.
The distribution of patients treated with unmodified cellu-
lose dialyzers was: 75.3% of patients at HUMC, 7.9% of
patients at the VAMC, and 29.5% of patients at GWUMC.
There was no difference between the mean age or the
proportion of patients with diabetes mellitus treated with
each type of dialyzer (ANOVA). Fewer women were
treated with synthetic, and more were treated with unmod-
ified cellulose dialyzers, in part because of the lower
proportion of women treated at the VAMC (ANOVA).
The mean serum albumin concentration was lower in
patients treated with modified cellulose compared with
unmodified cellulose and synthetic dialyzers (3.54 6 0.51
vs. 3.88 6 0.47, and 3.93 6 0.41 g/dl, P , 0.0001, ANOVA).
Mean Kt/V was not significantly different in patients
treated with synthetic (1.28 6 0.35), unmodified (1.19 6
0.28) or modified cellulose dialyzers (1.24 6 0.33,
ANOVA).
Immune parameters
Intrassay and interassay coefficients of variation for
circulating cytokine measurements (15 repetitive samples
performed on five separate days) ranged between 2.18 and
4.59%. There was no difference in mean level of circulating
cytokines between the men and the women in the control
group. The mean level of all the circulating cytokines was
Table 1. Patient demographics of the study
Site N Male Female White Black Hispanic
GWU 78 49 29 12 65 1
HUH 89 50 39 0 89 0
VAMC 63 60 3 3 60 0
Total 230 159 71 15 214 1
Abbreviations are: GWU, George Washington University; HUH,
Howard University Hospital; VAMC, Veterans Affairs Medical Center.
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lower in the healthy control group compared with the HD
patients (Table 2). There was no difference in the mean
level of any assessed immunologic parameter between the
three groups of patients treated with different dialyzers,
with the exception of T-cell recall function (greater in the
group treated with modified cellulose dialyzers, compared
with unmodified cellulose and synthetic dialyzers: 22.8 6 10
vs. 20 6 11.2, 17.2 6 11.2 SI units, P , 0.035, ANOVA).
There was no difference in mean levels of assessed immu-
nologic parameters in patients with and without diabetes
mellitus. Patients’ individual immune parameters at first
assessment and thereafter all also correlated highly (r range
0.65 to 0.90, all P , 0.001).
The mean immune parameters for the entire patient
population are outlined in Table 2. Two distributional
patterns were noted. In the first set (T-cell number and
recall function, CH50, IL-2, IL-4, IL-5, and IL-12), rela-
tively low levels of skewness were noted (Fig. 1). In the
second case (IL-1, IL-6, IL-13, and TNF-a) the distribution
was highly positively skewed (Fig. 2). In all cases, circulat-
ing cytokine levels were higher in patients treated with HD
compared with the normal controls (Table 2).
Correlations of medical, nutritional, dialytic and
immunologic data
Patients’ serum albumin concentrations were correlated
with levels of Kt/V (r 5 0.18, P 5 0.008) and PCR (r 5 0.27,
P 5 0.0001), and their circulating and log transformed
IL-13 and TNF-a levels (r 5 0.17, P 5 0.01, r 5 0.19, P 5
0.005; r 5 0.17, P 5 0.005, r 5 0.17, P 5 0.01, respectively).
In contrast, higher serum albumin concentrations were
correlated with lower circulating and log transformed IL-2
levels (r 5 20.17, P 5 0.009, and r 5 20.18, P 5 0.008,
respectively), T-cell number (r 5 20.23, P 5 0.0006) and
T-cell antigen recall function (r 5 20.19, P 5 0.004). Lower
T-cell antigen recall function correlated with higher values
of PCR (r 5 20.21, P 5 0.002), but there was no correla-
tion of T-cell number or function with Kt/V. There was no
correlation of any other immune parameter and medical or
demographic factor, including anthropometric indices.
There was no correlation of the duration of the patients
treatment for ESRD with any circulating cytokine. In fact,
the correlation that most closely approached the level of
significance (r 5 20.14, P 5 0.03) showed that IL-5 levels
were higher in patients more recently starting ESRD
therapy. Levels of all untransformed and log-transformed
immune parameters, however, were all highly intercorre-
lated (P 5 0.001).
Survival analysis
Because of the paucity of differences between mean
levels of immunologic parameters between groups of pa-
tients treated with different types of dialyzers, the small
number of patients treated with modified cellulose dialyz-
ers, and the findings of Hakim et al [7], survival analyses
were performed comparing patients treated with unmodi-
fied cellulose dialyzers with the group treated with modified
cellulose and synthetic dialyzers (Table 3). There was no
difference in mean age, severity coefficient, serum albumin
concentration, or percentage of patients with diabetes
mellitus between patients treated with unmodified cellulose
dialyzers and other types of dialyzers (Table 3). Mean Kt/V
was higher in the patients treated with modified and
synthetic dialyzers, compared with those treated with un-
modified cellulose dialyzers (1.29 6 0.34 vs. 1.17 6 0.27;
P 5 0.006, unpaired t-test). There was no difference in
mean CH50 or cytokine (IL-1, IL-2, IL-4, IL-5, IL-6, IL-12,
IL-13, or TNF-a) levels, T-cell number or T-cell recall
function between the two groups.
A Cox regression applied to the entire sample confirmed
an increased mortality risk for each decade increase in age
(50%, P , 0.0001), for patients with compared to those
without diabetes mellitus (57%, P , 0.05), and for a one
unit increase in severity coefficient (80%, P 5 0.0001; Table
4). There was a 30% decrease in risk for each 1 g/dl
increase in serum albumin concentration, controlling for
severity coefficient (P 5 0.007). An association between
increased mortality risk and gender or level of Kt/V,
controlling for severity coefficient, could not be demon-
strated in this comparatively small population. Although
patients treated with modified cellulose and synthetic dia-
lyzers had a 34% decreased mortality risk compared with
those treated with unmodified cellulose dialyzers, control-
ling for severity coefficient, the difference did not quite
achieve the level of significance (P 5 0.08).
Doubling of levels of circulating proinflammatory cyto-
kines IL-1, and TNF-a were associated with a 72% and
65% increase in mortality risk in this patient population
(C.I. 1.37 to 2.15 and 1.31 to 2.08 respectively, P , 0.0001),
controlling for variations in age, severity coefficient, serum
albumin concentration, dialyzer type and study site (Table
5). In contrast, higher levels of circulating IL-2, T-cell
number and function, and CH50 were associated with
improved survival (35%, 38%, 35% and 35% decrease in
mortality risk, P , 0.001, , 0.0001, , 0.001, and , 0.001,
Table 2. Mean values of circulating cytokines in controls and ESRD
patients
Controls
(N 5 28)
Patients
(N 5 230)
PMean SD Mean SD
IL-1, pg/ml 9.7 3.1 87.8 112.0 0.0001
IL-2, pg/ml 11.6 3.3 15.8 7.7 0.008
IL-4, pg/ml 9.4 2.5 131.5 63.5 0.01
IL-5, pg/ml 8.5 2.4 127.4 60.9 0.002
IL-6, pg/ml 13.3 3.1 92.3 117.9 0.0001
IL-12, pg/ml 9.0 2.7 14.1 6.4 0.0002
IL-13, pg/ml 11.1 2.4 29.2 3.1 0.01
TNF-a, pg/ml 13.3 3.0 114 147 0.0001
CH50, units/ml 64.5 9.6 55.0 18 0.02
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respectively). Doubling of levels of circulating IL-4, IL-5
and IL-12 were associated with improved survival as well
(36%, 34% and 24% decrease in mortality risk, P , 0.001,
, 0.001 and 5 0.02, respectively), while 100% increases in
levels of IL-6, and IL-13 were associated with a 56%, and
58% increase in mortality risk in this patient population
(P , 0.0001 and , 0.001, respectively). There was no
difference in these findings when the association of the
immune factors was controlled solely for age, severity of
comorbid illness and level of serum albumin concentration,
with the exception that the relative risk of the association of
survival with the level of circulating IL-12 decreased to 0.82
(C.I. 0.65 to 1.03, P 5 0.09). Similarly, there was no
difference in the results (compared with those outlined in
Table 5) when only the patients who had been dialyzed for
more than six months were assessed.
DISCUSSION
Henderson, Koch, Dinarello and Shaldon proposed the
“Interleukin Hypothesis” in 1983, suggesting that cytokine
stimulation by dialysis membranes might be associated with
many of the symptoms of uremia that persist, even in
seemingly well dialyzed patients [25]. We have demon-
strated that variations in levels of circulating cytokines in
hemodialysis patients are associated with changes in mor-
tality risk, in a patient population exhibiting demographic
and mortality markers comparable to those in the United
Fig. 1. Distribution of immune parameters in 230 stable outpatients with end-stage renal disease (ESRD) treated with hemodialysis. Distributions of
IL-2 (A), CH50 (B), T-cell number (C) and T-cell function (D) show moderate skew (skewness values ranging from 20.45 to 0.33). These factors were
associated with improved patient survival.
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States ESRD program [1, 26, 27]. Proinflammatory cyto-
kines such as IL-1 and TNF-a [28] were independently
associated with mortality in HD patients, while circulating
levels of IL-2 and IL-12, cytokines critical for T-cell growth
and function [28], IL-4 and IL-5, T-cell number and
functional status, and CH50 were independently associated
with survival.
The pattern of cytokines elaborated, reflecting the level
of activation and the interaction of the immune network in
a given patient, may be more important than their individ-
ual levels. Indeed, our data suggest that levels of particular
cytokines, while predictive of mortality, may not be tightly
causally linked to effectors of outcome. For example, IL-1
(a mortality factor in this study) increases synthesis of IL-2
(a correlate of survival) by lymphocytes, suggesting its
association with mortality must be mediated through other
pathways. Similarly, IL-4 (associated with survival in this
study) and IL-6 (associated with mortality) both decrease
Fig. 2. Distribution of immune parameters in 230 stable outpatients with ESRD treated with hemodialysis. Highly positively skewed distributions of
circulating IL-1 (A), IL-6 (B), TNF-a (C) and IL-13 (D) levels were noted in this population (skewness values ranging from 1.25 to 3.3). Most patients’
values were within a lower range, with a minority having extremely elevated values. These factors were associated with increased patient mortality.
Table 3. Characteristics of patients treated with different dialyzers
Modified cellulose
and synthetic
dialyzers
Unmodified
cellulose dialyzers
N Mean SD N Mean SD
Age, years 126 54.2 13.7 104 54.6 15.0
Diabetes, % 52.6 47.4
Severity coefficient 2.4 0.94 2.4 1.0
Serum albumin, g/dl 3.9 0.42 3.8 0.5
Kt/V 1.29 0.35 1.17 0.27a
IL-1, pg/ml 82.3 104.4 94.7 120.8
IL-2, pg/ml 16.6 7.6 15.4 7.9
IL-4, pg/ml 12.5 6.0 13.9 6.7
IL-5, pg/ml 12.3 5.9 13.3 6.3
IL-6, pg/ml 89.8 115.2 95.4 121.7
IL-12, pg/ml 14.3 6.5 14.0 6.4
IL-13, pg/ml 30.4 35.0 27.9 25.2
TNF-a, pg/ml 106.6 140.7 123.9 154.5
T-cells/1028/liter 49.5 10.1 50.2 9.8
T-cell RECALL, SI units 18.5 11.0 20.2 11.4
CH50, units/ml 54.1 0.3 55.4 18.2
a P 5 0.006.
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production of IL-1 and TNF-a by monocytic cells, suggest-
ing more complex effector routes must be present to foster
such outcomes in HD patients. Cytokines are thought to
exert their major physiologic and pathophysiologic effects
at local, cellular levels. The physiologic importance of
circulating cytokines is unknown, but infusion of cytokines
has been used in various in vivo animal models of disease
pathogenesis. We have argued in the past that the best way
to assess functional aspects of cytokine dysregulation is in
an in vitro cell system, under controlled, stimulated condi-
tions, normalizing for immune cell number and subset type,
and the ionic and protein microenvironment [9, 29]. How-
ever, in light of recent technical advances, it is clearly easier
to assess circulating cytokines in the clinical setting. The
level of circulating cytokines may be affected by many
parameters such as the level of residual renal function and
dialyzer clearances, differential absorption of cytokines to
different dialyzer materials, variable ultrafiltration rates,
differential cellular production, and different renal and
comorbid diseases in a population using heterogeneous
drugs [9, 10]. Certain patterns of cytokines may, however,
be critically associated with other common antecedent
medical conditions or host factors that diminish survival in
ESRD patients treated with dialysis, such as atopy [30],
rendering them useful as markers. In this regard, circulat-
ing levels of IL-6 and TNF-a have been shown to correlate
with disease severity in several illnesses [10, 31]. Addition-
ally, increased levels of TNF-a and IL-6, and abnormal
regulation of IL-10 have been associated with an abnormal
outcome, diminished response to hepatitis B-virus vaccina-
tion, in patients with renal disease [32].
In this study, however, such immune factors were gener-
ally not associated with the measured medical, nutritional
or dialytic parameters. In this study, we could not show a
relationship between the level of circulating cytokines and
the duration of the patients treatment for ESRD, suggest-
ing the abnormally high levels were not solely associated
with the extent of residual renal function. In fact, there was
no difference in the interpretation of the results when only
patients dialyzed for more than six months before study
entry (presumed to have little residual renal function) were
asssessed, suggesting the inclusion of incident patients with
appreciable renal function had little impact on the predic-
tion of survival. Recent reviews [29, 33] have emphasized
the potential relationships between IL-1 and TNF-a and
catabolism, muscle proteolysis and malnutrition, but these
relationships could not be confirmed with anthropometric
indices and nutritional parameters in this study. Paradoxi-
cally, higher serum albumin levels, often linked with sur-
vival in other studies of ESRD patients [reviewed in 10, 26],
were associated with cytokines strongly predictive of mor-
tality, such as IL-13, while lower albumin levels were
associated with “protective” immune factors, such as IL-2
and T-cell number and function, corroborating the nutri-
tion-independent associations of the immune parameters
with survival in this study. This may be due to the role of
some cytokines as acute phase reactants, which are associ-
ated with diminution in serum albumin levels [10, 26, 28].
Alternatively, the circulating cytokine levels may not be
closely associated with certain tightly-regulated cellular
physiological processes. The interaction of these systems
may ultimately be as important to patient survival as the
provision of optimal dialysis. While immune imbalance may
be associated with mortality, since individual cytokines
have multiple synergistic and antagonistic actions and
affect different cellular targets, particular cytokine combi-
nations may have unpredictable effects on various cellular
and organ systems, leading to differential outcomes.
Additionally, the source of the circulating cytokines
measured in the study, and their mechanistic role in
affecting outcome are unclear. TNF-a, IL-1 and IL-6 are
made by many cells, while IL-2, IL-4 and IL-5 are only
synthesized by lymphoid cells [28]. IL-4 is critical in regu-
lating B-lymphocyte function and circulating immunoglob-
ulin levels, and blocks monocyte production of IL-1, IL-6
and TNF-a. Both IL-2 and IL-4 increase T-cell maturation
and cytotoxicity [34]. One interpretation of the current
findings is that cytokines reflecting monocytic cell activa-
tion are associated with poor outcome, while better T cell
function and humoral immunity are associated with a
survival advantage in patients treated with hemodialysis.
This interpretation is bolstered by the findings related to
Table 4. Medical relative mortality risk factors in 230 hemodialysis
patients
Risk factor Alive Died Range
RR and 95%
CI P value
1 Age (in
decades)
153 77 1.9–8.4 1.5 (1.3, 1.8) , 0.0001
2 Diabetes 153 77 1.0–2.5 1.57 (1.4, 1.8) , 0.05
3 Severity 153 77 1.4–2.2 1.8 (1.7, 1.9) , 0.0001
4 Albumin 153 77 0.3–0.8 0.7 (0.6, 0.9) 0.007
5 Dialyzer Type 153 77 0.4–1.1 0.66 (0.4, 1.04) 0.08
Note: Albumin and dialyzer type are controlled for severity.
Table 5. Immune parameters predicting mortality controlling for age,
severity, dialyzer type, albumin and site
Parameter
Standardized
RR and 95%
CI P value
Log IL-1 1.72 (1.37,2.15) , 0.0001
Log IL-2 0.65 (0.51,0.81) , 0.001
Log IL-4 0.64 (0.51,0.80) , 0.001
Log IL-5 0.66 (0.52,0.83) , 0.001
Log IL-6 1.56 (1.25,1.94) , 0.0001
Log IL-12 0.76 (0.60,0.96) 0.02
Log IL-13 1.58 (1.25,2.00) , 0.001
Log TNF-a 1.65 (1.31,2.08) , 0.0001
T-cell (div by 4) 0.62 (0.49,0.78) , 0.0001
T-cell recall (div by 5) 0.65 (0.51,0.83) , 0.001
CH50 (div by 60) 0.65 (0.52,0.82) , 0.001
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outcome documented by Girndt et al [32]. These effects
may be mediated through resistance to infection, the
second most prevalent cause of death in the ESRD popu-
lation [1]. Such notions are also supported by our finding of
the association of increased levels of CH50, a measure of
the ability to opsonize and lyse bacteria, clear immune
complexes, and enhance neutrophil, monocyte and B-
lymphocyte function, with enhanced survival [35]. Another
possibility is that patients with the highest levels of proin-
flammatory cytokines have reacted to the presence of
endotoxins, secondary to infection or as a complication of
dialysis [36]. The presented data cannot distinguish be-
tween these possibilities.
Recent studies demonstrated a survival advantage in
patients treated with modified cellulose or synthetic dialyz-
ers [7]. The authors considered that differences in their
“biocompatibility” resulting in less immune stimulation in
patients treated with synthetic or modified dialyzers might
underlie this effect, or that other factors, such as differ-
ences in gross amount or type of molecular clearance,
dialytic bath or mechanical factors might be associated with
improved survival. With the exception of T-cell recall
function, there were no differences in immune parameters
measured before the start of a dialysis session between
groups of patients treated with the various types of dialyz-
ers in this study. Our findings suggest that differences in
patients’ pre-treatment immune function are quantitatively
relatively more important than the type of dialyzer used in
their treatment, but do not directly underlie differential
survival in patients treated with different types of dialyzers.
Rather, the higher dose of dialysis, or differences in middle
molecule clearance may be related to survival in patients
treated with newer types of dialyzers. We expect that with
a larger number of patients who are followed for a longer
period of time, however, the differences in survival between
patients treated with different types of dialyzers would
reach the level of statistical significance. Whether differen-
tial effects on patients’ immune status after hemodialysis
are associated with these findings must be addressed in
further studies.
Variations in the immune parameters were associated
with changes in the relative risk of mortality in the range of
magnitude of effects that age, presence of diabetes melli-
tus, severity of comorbid illness and level of serum albumin
concentration displayed, even when the variations of these
parameters were controlled in the analysis. We could not
demonstrate an association between immune parameters
and Kt/V or PCR. Our population had a relatively high
Kt/V and adequate nutritional status [15, 16, 27]. The effect
of increasing the dose of dialysis provided may be seen only
in relatively large populations with longer observation
periods. Additionally, there may be diminished returns of
increasing delivery of dialysis when the Kt/V achieved is
already high. Such questions are currently being addressed
in prospective studies.
Our study population was primarily comprised of Afri-
can-American, urban patients. Our present findings must
be replicated in larger and more diverse populations to
establish the generalizable and specific findings reported.
In addition, because of the exploratory nature of the
present study, we did not measure the level of circulating
cytokines after hemodialysis. We and others [9; reviewed in
10, 30, 32, 37] have previously shown that cytokine metab-
olism may alter markedly after treatment. The relationship
between immune parameters before and after dialysis, and
the effect of interventions designed to normalize the im-
munologic status of ESRD patients treated with hemodial-
ysis on survival should be studied.
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